The alanine transaminase (ALT), platelet, albumin, and AFP levels before DAA treatment differed significantly between the SVR-HCC and SVR-non-HCC patients (Table 7 and Table S1). The gene discussed is GPT; the disease is hepatocellular carcinoma.